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Abstract Celecoxib, a selective cyclooxygenase-2 inhibi-
tor, has shown potential anticancerous activity against
majority of solid tumors especially on patients with colon
cancer. However, associations of serious side effects limit
the usage of celecoxib in colon cancer treatment. To address
this issue and provide an alternative strategy to increase the
efficacy of celecoxib, liposomal formulation of celecoxib
was prepared and characterized. Anticancer activity of
liposomal celecoxib on colon cancer cell HCT 15 was
evaluated in vitro. Furthermore, tumor inhibition efficiency
by liposomal celecoxib was studied on 7,12-dimethyl benz
(a)anthracene (DMBA)-induced tumor in rat model. In
order to elucidate the antioxidant activity of celecoxib-
loaded liposomes, antioxidant superoxide dismutase (SOD)
generation and lipid peroxide (LPx) formation in both liver
and kidney tissues were examined. Characterization of the
formed unilamellar liposomes revealed the formation of
homogeneous suspension of neutral (empty) or anionic
(celecoxib-loaded) liposomes with a well-defined spherical
shape which have a mean size of 103.5 nm (empty
liposome) and 169 nm (liposomal celecoxib). High-
performance liquid chromatography (HPLC) analysis and
hemolytic assay demonstrated 46% of celecoxib entrapment
efficiency and significantly low hemolysis, respectively.
Liposomal celecoxib exhibited dose-dependent cytotoxicity
and apoptotic activity against HCT 15 cells which are
comparable to free celecoxib. In vivo study demonstrated
inhibition of tumor growth. Biochemical analysis of the
liposomal celecoxib-treated group significantly inhibited
the LPx formation (oxygen-free radicals) and increased the
activity of SOD. Our results present the potential of
inhibiting colon cancer in vitro and DMBA-induced tumor
in rat model in vivo by liposomal celecoxib.
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1 Introduction
Chemotherapeutic agents used for cancer treatment have
large volume of distribution upon intravenous administra-
tions which result in narrow therapeutic index, unsolicited
drug distribution, and high level of toxicity in healthy
tissues (Turanek et al. 2009). In the recent years, several
research works have manipulated pharmacokinetic and
biodistribution properties of drug-loaded lipid/polymer
nanocarriers to improve the anticancer activity (Yang et al.
2007; Lu et al. 2008; Nakano et al. 2008; Hiremath et al.
2009). The nanocarriers should be long circulating in blood
in order to passively target tumor tissue through enhanced
permeability and retention effect (EPR) (Katanasaka et al.
2008). Among the several nanocarriers, liposomes are
extensively used for drug delivery and modeling of cell
membrane to elucidate their endocytosis mechanisms
(Nakano et al. 2008; Hiremath et al. 2009). Liposomes are
sophisticated and handy nanodelivery systems which
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facilitate targeted drug delivery, thereby reducing organ-
specific side effects of several anticancer agents (Abu Lila
et al. 2009). Liposomal formulation of hydrophobic drugs
has been reported to overcome the solubility and the
solvent-induced side effects (Katanasaka et al. 2008). In
vivo studies using liposomal formulations have also been
reported to reduce anticancer agent-mediated toxicities
(Storm et al. 1987; Turanek et al. 2009). Indeed, the
liposomal formulation of anticancer agents approved for
medical applications are daunorubicin (DaunoXome) and
DOX (Doxil; Drummond et al. 1999). Liposomal formula-
tion of paclitaxel and doxorubicin are the prime examples
for enhanced solubility and reduced cardiotoxicity profile,
respectively (Yang et al. 2007; Tan et al. 2010).
Among the different types of cancer, colon cancer is the
second leading cause of cancer-related deaths worldwide.
According to the World Health Organization (WHO) report,
colon cancer accounts for 677,000 deaths per year (Auman et
al. 2008). Commonly used first-line chemotherapeutic
regimens for colon cancer involve combination of infusional
5-fluorouracil, leucovorin, and oxaliplatin with bevacizumab
or infusional 5-fluorouracil, leucovorin, and irinotecan with
bevacizumab (Gaiser et al. 2008). Despite the chemotherapy,
solubility and organ-specific toxicity associated with several
anticancer agents necessitate designing effective formulation
to treat colon cancer.
Within the family of non-steroidal anti-inflammatory
drugs, celecoxib has been most frequently investigated
for its anticancer activity against various in vitro and in
vivo models (Hsiao et al. 2007; Bijman et al. 2008;
Dhawan et al. 2008; Fig. 1a). Preclinical studies using
celecoxib have reported prominent anticancer activity
against head and neck squamous cell carcinoma, colon
cancer, breast cancer, and lung cancer (Hsiao et al. 2007;
Bijman et al. 2008). Despite the approval of celecoxib
(oral administration) by FDA (Food and Drug Adminstra-
tion) of USA for adjuvant therapy in patients with familial
adenomatous polyposis and precancerous disease of colon,
association of greater intensity of side effects (thrombo-
embolism and cardiovascular risk) and poor water solu-
bility limit its usage in cancer therapy (Mazhar et al. 2006;
Mohammed et al. 2006; Auman et al. 2008). It has also
been reported that celecoxib is rapidly eliminated from
plasma which limits therapeutic concentration of cele-
coxib at tumor sites (Paulson et al. 2000, 2001).
Therefore, it is more essential to find alternative method
Fig. 1 a Structure of celecoxib; AFM images of b and c empty liposomes and d and e celecoxib-loaded liposomes; TEM images of f empty
liposomes and g celecoxib-loaded liposomes
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for celecoxib administration, i.e., specific drug delivery
systems to reduce the side effects and to increase
anticancer activity. So, it is hypothesized that liposomal
formulation of celecoxib might provide a novel ap-
proach to circumvent the poor solubility, to improve the
therapeutic index, and to diminish cardiotoxicity in-
duced by celecoxib (Maier et al. 2004; Hsiao et al. 2007;
Sakoguchi-Okada et al. 2007; Bijman et al. 2008; Gaiser
et al. 2008). To the best of our knowledge, no studies have
been reported using effect of liposomal celecoxib on colon
cancer. In view of the above, liposomal celecoxib was
prepared and characterized for morphology, size, zeta
potential, entrapment efficiency, and hemocompatibility.
Anticancer activity of liposomal celecoxib was analyzed
by cell proliferation assay, morphological, cell cycle, and
apoptosis analysis. Furthermore, tumor inhibitory effect of
liposomal celecoxib was evaluated on DMBA-induced rat
tumor model.
2 Materials and methods
DSPC (1,2-distearoyl-sn-glycero-phosphatidylcholine),
MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium
bromide), PI (propidium iodide), DAPI (4′,6-diamidino-2-
phenylindole), reduced glutathione, DTNB (5,5-dithiobis
(2-nitrobenzoic acid)), RNase (ribonuclease), and
DMBA were obtained from Sigma Aldrich, USA.
Synthetic grade of methanol and chloroform was
obtained from Merck, India. Celecoxib was generously
provided by Aarthi Drug Ltd, Mumbai, India. HEPES
was obtained from Sisco Research Labs. Animal food
pellet was supplied by Hindustan Lever Ltd, Mumbai,
India. Phosphotungstic acid, thiobarbituric acid, trichloro-
acetic acid, acetic acid, sodium salicylate, and EDTA
were purchased from the Himedia Chemicals (Pvt) Ltd,
Mumbai, India. Ascorbate, FeCl3, sodium tungstate,
sodium nitrate, methanol, and other reagents were of
analytical grade. All other chemicals were of highest
possible grade and obtained from commercial sources. The
chemicals were used as supplied.
2.1 Cell culture and conditions
Human colon cancer cell line HCT 15 (National Centre for
Cell Science (NCCS), Pune, India) was grown as adherent
culture in RPMI 1640 medium (Himedia, India) supple-
mented with 10% FBS (Gibco®, Invitrogen, India), 2 mM
L-glutamine, 100 units/ml penicillin, and 0.1 mg/ml
streptomycin (Himedia, India) at 37°C and 5% CO2 in air.
After the cells became 80% confluent (usually after 3 days),
they were trypsinized (0.25% trypsin+0.1% EDTA), centri-
fuged (Heraeus table top centrifuge E003) and suspended in
medium. For subsequent experiments, the cells were seeded
in 96-well plate, cover slip, and 60 mm Petri dish.
2.2 Preparation of liposomal celecoxib
Empty and celecoxib-loaded liposomes were prepared
using modified thin film method as stated by Bangham et
al. (Sadzuka et al. 2005). Briefly, phospholipid (DSPC) and
celecoxib were dissolved together in methanol with the
lipid to drug ratio of 4:1 w/w in a round-bottom flask. The
solvent was then evaporated in a Bǜchii rotoevaporator to
form a thin film along the wall of the flask. It was attached
to high vacuum for 2 h to remove any traces of the solvent.
To the dry film, HEPES buffered saline (10 mM HEPES
and 150 mM NaCl) was added and agitated above the gel
transition temperature of DSPC. The liposomal suspension
was then freeze-thawed for five times by alternately
freezing in liquid nitrogen and then subsequently bringing
above its gel transition temperature. The formed multi-
lamellar vesicles were then sonicated using ultra sonic
probe (Cole Parmer CP-18) for 20 min to obtain an
optically clear solution. The resultant unilamellar vesicles
were then centrifuged for 15 min at 4°C and 10,000 rpm
to remove phospholipid residue and titanium impurity.
The visibly clear supernatant was withdrawn and stored
at 4°C. The liposomal solution was ultracentrifuged
(Sorvall Ultra Pro 80) at 120,000×g force at 4°C for 2 h
to remove any unencapsulated celecoxib. Supernatant was
discarded, and pellet was resuspended in HEPES buffered
saline (pH 7.0) to a final phospholipid concentration of
2 mg/ml. All experiments were performed with freshly
prepared liposomes.
2.3 Analysis of liposomes using AFM and TEM
Vesicle formation and morphology of liposomes were
analyzed using atomic force (AFM, Veeco CPII, USA)
and high-resolution transmission electron (HRTEM, JEOL
JEM) microscopies. The liposome samples were diluted
(tenfold with 10 mM HEPES buffer saline), added to a
freshly cleaved mica sheet and allowed to remain in contact
for 5 min. From the mica sheet, excess sample was
removed, dried, and analyzed using tapping mode AFM
(Li et al. 2008; Nakano et al. 2008). The tapping mode
settings were as follows—0.5 Hz scan rate, resolution of
256×256 data points per scan, AV-shaped silicon nitride
cantilever (MMP-11123, Veeco Instruments Inc., USA)
having spring constant 40 N/m, length 115–135 μm, and
radii of curvature <10 nm.
For transmission electron microscopy (TEM) analysis,
the diluted liposomes were applied to carbon-coated copper
grids and negatively stained with 1% ammonium molyb-
date solution (pH 7.0). The excess of liposomes were
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removed from the grid and dried for further analysis. Three
grids were prepared for each sample.
2.4 Particle size and zeta potential measurement
The mean particle size, polydispersity index, and zeta
potential of empty and celecoxib-loaded liposomes were
measured by DLS (dynamic light scatter, Nano-ZS, Mal-
vern Instrument, UK). HEPES buffered saline diluted
liposome samples were backscattered by a helium-neon
laser (633 nm) at an angle of 173° and temperature of 25°C
(Zhang et al. 2008; Turanek et al. 2009; Yang et al. 2009).
Mean surface charge was calculated from samples taken in
triplicate and analyzed based on Gaussian size distribution.
2.5 Entrapment efficiency
A known volume of liposomal celecoxib was diluted into
suitable concentration with methanol. It was then bath-
sonicated to disrupt the liposomes and release the encapsu-
lated celecoxib. The amount of encapsulated celecoxib in
liposomes was quantitatively determined using reverse
phase HPLC (Shimadzhu LC-10AD pump liquid chro-
matograph, Diamonsil® C-18 column, 250 mm×4.6 mm,
5 μm) using methanol/water (75:25 v/v) as mobile phase
(Saha et al. 2002). The analysis was performed at 20 μl
injection, 1.25 ml min−1 of flow rate, and UV detector at
250 nm (Baboota et al. 2007). Calibration curve was
constructed using celecoxib in the concentration range of
0–150 μM. Dilution factor was taken into consideration for
calculating the entrapment efficiency of celecoxib in
liposomes. The analysis was done in triplicate, and values
were reported as mean±SD. The percentage of celecoxib
entrapped in liposomes was calculated as: Entrapment
efficiency (%)=(Amount of encapsulated celecoxib/Total
amount of celecoxib)×100.
2.6 Hemocompatibility study
Free celecoxib, empty, and celecoxib-loaded liposomes
were diluted in 10 mM HEPES buffer saline to desired
concentrations. Hemocompatibility of different samples
were analyzed using a previous protocol with some
modification (Katanasaka et al. 2008). In brief, blood was
collected from 6-week-old BALB/c male mice and centri-
fuged (1,500×g for 5 min at 4°C using Ficoll density
gradient solution) to obtain red blood cells (RBC).
Collected RBC pellet was diluted with 20 mM HEPES
buffered saline (pH 7.4) to give a 5% v/v solution. The RBC
suspension was added to HEPES buffer saline, 1% Triton
X-100, free celecoxib, and empty and celecoxib-loaded
liposomes. All samples were incubated at 37°C for 30 and
60 min. After incubation, the samples were centrifuged at
12,000 rpm at 4°C, and supernatants were transferred to a
96-well plate. Hemolytic activity was determined by
measuring the absorption at 570 nm (Bio-rad, microplate
reader, model 550, Japan). Control samples of 0% lysis (in
HEPES buffer) and 100% lysis (in 1% Triton X-100) were
employed in the experiment (Guggi et al. 2004). The study
was performed in triplicate. Hemolytic effect of each
sample was expressed as percentage of cell lysis relative
to the untreated control cells (% control) defined as: [(OD
570 nm sample)/(OD 570 nm control)]×100, where optical
density was abbreviated to OD.
2.7 Cell proliferation assay
Cytotoxicity of free celecoxib, empty, and celecoxib-loaded
liposomes on colon cancer cells HCT 15 was determined by
cell proliferation assay as described previously (Yang et al.
2007). Briefly, HCT 15 cells in exponential growth phase
were seeded onto 96-well plates at a density of 5×103 cells
per well in 0.1 ml medium. Cells were allowed to adhere
and grow for 24 h at 37°C in an incubator (Heraeus Hera
Cell). Then, the medium was aspirated and replaced with
0.1 ml fresh medium containing various concentrations of
free celecoxib, empty, and celecoxib-loaded liposomes.
Control well was treated with equivalent volume of
celecoxib-free media. After 72 h of incubation, the medium
was removed, and cell viability was determined using a
conventional MTT dye reduction assay. Then, 100 μl of
1 mg/ml MTT reagent was added to each well. After 4 h
incubation, unreduced MTT solution was discarded. Then,
100 μl of dimethyl sulfoxide was added into each well to
dissolve purple formazan crystals which was reduced from
MTT by active mitochondria of viable cells. Plate was
shaken for 20 min, and formazan dye was measured
spectrophotometrically using a microplate reader. The
experiment was performed in triplicate. The cytotoxicity
of each treatment was expressed as percentage of cell
viability relative to the untreated control cells (% control)
defined as [(OD 550 nm treated cells)/(OD 550 nm control
cells)]×100, where optical density is abbreviated to OD.
2.8 Morphological analysis
HCT 15 cells were grown at a density of 3×104 in Petri
dishes and treated with absence (control) or presence of
IC50 concentrations of free celecoxib, liposomal celecoxib,
and empty liposomes (volume equivalent to liposomal
celecoxib) for 48 h. After incubation, morphological
changes were observed under phase contrast microscope
(Leica, ×20; Caddeo et al. 2008).
Furthermore, morphological analysis of cancer cells
using high-resolution scanning electron microscope
(SEM) was performed to obtain a clear insight regarding
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cell membrane extensions (filopodia and lamellipodia;
Venkatesan et al. 2010). HCT 15 cells grown on a sterile
cover slip were treated with free celecoxib (IC50),
liposomal celecoxib (IC50), and empty liposomes (equivalent
to volume liposomal celecoxib) for 48 h. Cells were washed
thrice in 0.1 M cacodylate buffer (pH 7.4) and post-fixed
using ice-cold 1% OsO4 for 30 min. Cells were then
dehydrated with grades (50%, 70%, 95%, and 100%) of
ethanol. Next, the cover slips were placed in HMDS
(1,1,1,3,3,3-hexamethyl disilazane) for 5 min to overcome
drying effect. Samples were then air-dried at room temper-
ature, mounted on a stub, and placed in vacuum chamber of
SEM gold coating apparatus for gold coating (2.5 kV, 20–
25 mA for 120 s). The morphogram of the HCT 15 cells was
then observed using SEM (JEOL JSM-5800 Japan) at 20 kV
acceleration voltage (Hodges 1970; Glaser et al. 1977).
2.9 Cell cycle analysis
HCT 15 cells at a density of 2×105 was cultured in 60 mm
Petri dishes for 24 h and then treated with free celecoxib
(IC50), empty liposomes (equivalent to volume liposomal
celecoxib), and celecoxib-loaded liposomes (IC50) for 48 h.
In this study, medium and empty liposome-treated cells were
used as reference control and blank formulation, respectively.
After incubation, HCT 15 cells were centrifuged at
1,200 rpm for 5 min at 4°C. The cell pellet was suspended
in 5 ml of PBS and then centrifuged at 1,200 rpm for 10 min
at 4°C. The supernatant was discarded, and the pellet was
fixed with 2 ml of ice-cold ethanol solution (70% v/v) at 4°C
overnight. Fixed cells were centrifuged at 1,200 rpm for
10 min at 4°C, and the pellet was incubated with PI mixture
(10 mg/ml RNase, 20 μg/ml PI in cold PBS) for 30 min at
37°C. DNA content analysis was carried out on a FACS
Calibur (BD Bioscience) flow cytometer (Celia et al. 2008).
The data obtained were processed for cell cycle analysis with
the Cell Quest Pro software package.
2.10 Nuclear analysis
Apoptosis of HCT 15 cells treated with free celecoxib,
empty, and celecoxib-loaded liposomes was analyzed by
epi-fluorescence microscopy. HCT 15 cells were seeded in
six-well plates containing a cover slip with 2×105 cells per
well and cultured at 37°C for 24 h. Cells were then treated
with free celecoxib (IC50), celecoxib-loaded liposomes
(IC50), and empty liposomes (equivalent to volume liposo-
mal celecoxib) and culture medium (control) for 48 h. Cells
were then fixed (2% ice-cold paraformaldehyde in PBS for
20 min), permeabilized (0.1% Triton X-100), stained (0.2 μg/
ml DAPI in PBS for 15 min), and washed twice with PBS.
Cover slips were mounted onto glass slides and examined
using a fluorescence microscope (Leica DMR, ×20). Apopto-
tic cells were evaluated based on nuclear morphology,
chromatin condensation, and fragmentation (Caddeo et al.
2008; Danhier et al. 2009).
2.11 Inhibition of DMBA-induced tumor in rat model
Female Wistar rats (6-week-old and 100 g of weight) were
divided into five groups containing six rats each. Rats were
maintained at 28±1°C, relative humidity at 60% (each 12 h
of light and dark cycle). These rats were fed with standard
food pellets (diet composition, broken wheat-moisture
9.0%, crude protein 11.5%, crude fat 1.9%, crude fiber
4.0%, Ash 0.2%, and nitrogen-free extract 73.4%) and tap
water ad libitum. The experimental procedures were carried
out with prior approval from animal ethical committee at
the university.
2.11.1 Experimental design, tumor induction, and inhibition
Rat tumors were induced by DMBA injection (Huggins et
al. 1961; Singh and Shukla 1998; Malejka-Giganti et al.
2000; Samy et al. 2006). DMBA (250 mg/kg) dissolved in
1 ml of vehicle (0.5 ml of sunflower oil plus 0.5 ml of PBS
saline) was injected subcutaneously near either side of
mammary glands. After 90 days of injection, tumor yield
and size were stabilized.
Inhibition of DMBA-induced tumor by free celecoxib,
empty, and celecoxib-loaded liposomes was determined. In
this study, group (I) rats were fed with standard food pellet and
tap water which served as a normal control. Rats with tumor
(group II) were kept as cancer control. After 90 days of
DMBA injection (after tumor formation), drug treatment was
initiated. Furthermore, the tumor-bearing rat groups (II, III, IV,
and V) were injected at tail vein with sterile PBS (cancer
control), free celecoxib, empty, and celecoxib-loaded lip-
osomes, respectively. Table 1 shows the dosage used in the
experiment. All the groups were treated for three times in
first 5 days and 1 day spaced between two injections. Rats
were regularly examined for food and water consumption,
apparent signs of toxicity and mortality for 30 days. At the
end of the treatment period (after 120 days), total body
weight of all rats was measured; they were starved overnight
and sacrificed by cervical decapitation. The tumor was
surgically dissected out and tumor volumes (Volume in cubic
millimeter) of both the cancer and treatment groups were
calculated with following formula: V=(L×W2)/2, where L
(millimeters) is the longest diameter and W (millimeters) is
perpendicular to L (Caddeo et al. 2008; Danhier et al. 2009).
2.12 Biochemical analysis of antioxidants
The following biochemical measurements were carried
out in the rat liver and kidney tissues. The organs were
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excised and removed from the experimental groups for
the estimation of antioxidant enzymes. Tissues were
washed thoroughly with ice-cold normal phosphate buffer
saline, pH 7.2 (PBS, 0.9%) and cut into small pieces
with a heavy-duty blade. Tissues were homogenized by a
glass homogenizer tube in cold PBS, and centrifuged at
20,000 rpm for 10 min, and the supernatant was diluted
with PBS up to a final protein concentration. Effects of
liposomal celecoxib on activities of SOD generation and
LPx were estimated in the liver and kidney tissues of
treated and control rats.
2.12.1 SOD radical scavenging activity
SOD activity was assessed by the Nitroblue tetrazolium
reduction method (Samy et al. 2006). Approximately, a
known protein concentration of tissue supernatant was
added to a reaction mixture containing 0.1 mM EDTA
(200 μl), 0.12 mM riboflavin (50 μl), and 0.6 M phosphate
buffer (pH 7.8) in a final volume of 3 ml. The optical
density was measured at 560 nm.
2.12.2 Inhibition of LPx formation
Induction by Fe3+/ascorbate system: the reaction mixture
containing rat liver and kidney homogenate (0.1 ml, 50%
w/v) in Tris–HCl (30 mM), ferrous ammonium sulfate
(0.16 mM), ascorbic acid (0.06 mM), and the reaction
mixture was incubated for 1 h at 37°C, and the resulting
thiobarbituric reacting substances were measured (Samy et
al. 2006). Briefly, a 0.4 ml aliquot of the reaction mixture
was treated with sodium dodecyl sulfate (0.2 ml, 8%),
thiobarbituric acid (1.5 ml, 0.8%), and acetic acid (1.5 ml,
pH 3.5), made up to a total volume of 4 ml by adding
distilled water, and then kept in a water bath at 95°C for
1 h. After cooling, 1 ml of distilled water and 5 ml of n-
butanol/pyridine (15:1 v/v) were added. The organic layer
was separated after shaking and centrifugation. LPx activity
was measured in terms of thiobarbituric acid formation and
the color intensity measured spectrophotometrically at
530 nm.
2.13 Statistical analysis
All the statistical analysis was performed by Graphpad
Prism 5 software. Data were presented using mean±SD.
The statistical significance was determined by using one-
way analysis of variance (ANOVA). ***P<0.001 and **P<
0.05 were considered significant.
3 Results and discussion
3.1 Analysis using AFM and TEM
The prepared liposomes appeared semi-transparent and
visible sky-blue opalescent dispersion. Previous studies
have reported that nature of phospholipid composition in
liposomal carrier have influence on its stability, entrapment
efficiency, and blood circulation time (Nakano et al. 2008).
Furthermore, rigidity of liposome particles was attributed to
phase transition temperature (55°C) of DSPC (Egawa and
Furusawa 1999; Nakano et al. 2008). Our AFM images of
both empty and celecoxib-loaded liposomes indicate
spherical-shaped homogeneous particles (Fig. 1b–e).
In addition, TEM analysis is a semi-quantitative tech-
nique, which provides enough information on morphology
of liposomes (Zhang et al. 2008). Under TEM analysis,
surface morphology is very distinct with well-formed
liposomes (Fig. 1f, g). The inner areas of both the
liposomes appeared gloomy which might be attributed to
dense packing of the lipid bilayer vesicles. The results
displayed discrete, homogeneous, round particles with size
of 125 and 170 nm for empty and celecoxib-loaded
liposomes, respectively.
3.2 Particle size and zeta potential measurement
The DLS analysis showed mean particle size of 103.5 and
169 nm for empty and celecoxib-loaded liposomes,
respectively. The results indicate formation of large uni-
lamellar liposome formulation prepared by modified thin
film method. Polydispersity index describes relative error
Table 1 Shows the experimental design, dosage, and treatment
Groups Experimental design Tumor induction (DMBA
treatment 250 mg/ml/kg rat)
Tumor inhibition (treatment: three times in the first 5 days through
tail vein injection, 1 day spaced between two administrations)
Group I Normal control – –
Group II Cancer control Once/3 months –
Group III Cancer + celecoxib Once/3 months Celecoxib (100 μg/kg diluted in PBS)
Group IV Cancer + empty liposome Once/3 months Empty liposome (equivalent volume of liposomal celecoxib) in PBS
Group V Cancer + liposomal celecoxib Once/3 months Equivalent to celecoxib concentration 100 μg/kg in PBS
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between curve fit and experimental values, which suggests
homogeneity of colloidal suspension. Polydispersity index
greater than 0.7 indicates that sample has a very broad size
distribution (Caddeo et al. 2008). In our study, polydisper-
sity index of empty and celecoxib-loaded liposomes was
determined as 0.604 and 0.409, respectively, which indicate
formation of homogeneous liposomes.
The zeta potential is a good index of degree of repulsive
interactions between colloidal particles. It depends on
particle composition, especially on the lipid concentration
and incorporated drug (Katanasaka et al. 2008; Jung et al.
2009). Surface charge (zeta potential) measurement of
empty and celecoxib-loaded liposomes have shown 0.11
and −8.22 mV, respectively. Since the phospholipid is
almost neutral in charge, negative surface charge of
celecoxib-loaded liposomes indicates likely association of
celecoxib in liposomes. Furthermore, high negative charge
of the liposomal celecoxib leads to high repulsive force
between particles which might prevent aggregation lipo-
some particles.
3.3 Entrapment efficiency of liposomes
The amount of celecoxib encapsulated in liposomes was
determined by HPLC analysis. The study result shows 46%
of entrapment efficiency, which indicates good incorpora-
tion potential of the prepared liposomes.
3.4 Hemocompatibility study
Intravenous administration of a drug is limited by proper-
ties like solubility, hemolysis, and toxicity. Liposomal
formulations of hydrophobic drugs have been reported to
overcome the solubility problem and hemolytic activity of
free drugs (Guggi et al. 2004; Katanasaka et al. 2008).
Hemolytic assay was performed to examine interaction
between the anionic liposomal celecoxib and anionic red
blood cell membrane (Katanasaka et al. 2008). The
membrane-damaging property of liposomes was determined
by measuring released hemoglobin.
To resolve whether liposomalization of celecoxib prevent
hemolysis, the hemolytic assay was performed. Free
celecoxib suspended in HEPES buffer saline induced
significant hemolysis which might be attributed to SO2NH2
group present in celecoxib (Guggi et al. 2004). The
interaction between the RBC and free celecoxib might
induce membrane twist, cell rupture, and release of
hemoglobin. However, empty and celecoxib-loaded lip-
osomes exhibited significantly low hemolytic activities
(Fig. 2a) that can be ascribed to rigidity of liposomes and
electrostatic repulsion with anionic RBC (Nakano et al.
2008; Jung et al. 2009). Rigid molecules (e.g., DSPC) are
less prone to attach to RBC membrane than flexible
molecules, which would explain low hemolytic activities
of both empty and celecoxib-loaded liposomes.
3.5 Cell proliferation assay
Compared with the free paclitaxel, liposomal formulation of
paclitaxel has demonstrated enhanced solubility and cyto-
toxicity against variety of cancer cell lines (Yang et al.
2007). In this study, cytotoxicity of liposomal celecoxib and
free celecoxib was investigated on HCT 15 cells using
widely established metallothionein (MTT) assay. Both free
Fig. 2 a Hemolytic assay. In brief, red blood cells were collected by
centrifugation of mice blood and resuspended in HEPES buffer saline
(5% v/v). The cell suspension was added to HEPES buffer saline, 1%
Triton X-100, free celecoxib, and empty and celecoxib-loaded
liposomes, and incubated for 30 and 60 min at 37°C. After
centrifugation, hemolytic activity was determined by measuring the
absorbance of the supernatants at 570 nm. Control samples of 0% lysis
(in HEPES buffer) and 100% lysis (in 1% Triton X-100) were used in
the experiment. The bars indicate the mean±SD (n=3). Significant
difference is shown as **p<0.05; ***p<0.001 versus + control. b
Antiproliferative activity of free celecoxib and liposomal celecoxib on
HCT 15 cells. Each point in the graph indicates the mean±SD (n=3)
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celecoxib and liposomal celecoxib have significantly
inhibited HCT 15 cells proliferation in a dose-dependent
manner. The IC50 value of the free celecoxib on HCT 15
cell was a little lower (102.71 μM) than liposomal
celecoxib (IC50 127.67 μM; Venkatesan et al. 2010).
Furthermore, free celecoxib displayed low cell viability
compared with liposomal celecoxib which might be due to
higher intracellular uptake of free celecoxib by HCT 15
cells (Fig. 2b; Caddeo et al. 2008; Celia et al. 2008; Abu
Lila et al. 2009). In contrast, low cytotoxicity mediated by
liposomal celecoxib might be ascribed to low intracellular
uptake resulting from electrostatic repulsion between cells
(anionic) and liposomes (anionic), and slow release of
celecoxib. This results in reduced intracellular concentra-
tion of celecoxib in the cells. As expected, the empty
liposomes did not show growth inhibitory activity on HCT
15 cells at volume equivalent to the celecoxib-loaded
liposomes (data not shown). This observation substantiates
that the cytotoxicity of liposomal celecoxib on HCT 15
cells is due to the celecoxib released from liposomes than
the carrier itself (phospholipid).
3.6 Morphological analysis
Morphological analysis of HCT 15 cells treated with free
celecoxib, empty, and celecoxib-loaded liposomes was
performed using phase contrast microscope (Leica, ×20).
The control HCT 15 cells displayed confluent monolayer,
and elongated and flattened cell morphology (Fig. 3a).
Furthermore, empty liposome-treated HCT 15 cells
exhibited proliferated cell with no significant morphologi-
cal changes. In contrast, free celecoxib- and liposomal
celecoxib-treated HCT 15 cells have shown significant
morphological changes which include small group of
shrunken and retracted cells from substratum.
SEM is a vital tool to analyze surface and morpho-
logical features of cancer cells. Many researchers have
used SEM for morphological analysis of normal and
cancer cells (Jacobs et al. 1976). SEM analysis of
osteosarcoma has revealed a close relationship between
cell morphology and its function (Docheva et al. 2008).
Previous study of AEE788- and/or celecoxib-mediated
morphological changes used SEM to evaluate the antican-
cer activity. Anticancer agent-mediated morphological
changes in cancer cell may potentially be valuable for
cancer chemotherapy (Venkatesan et al. 2010). The study
was aimed to analyze morphology of celecoxib, empty,
and celecoxib-loaded liposome-treated HCT 15 cells.
From the obtained SEM image (Fig. 3b), the control
HCT 15 cells have shown highly dynamic, flat cell with
filamentous lateral cell membrane extensions (filopodia
and lamellipodia). In contrast, free celecoxib- and liposo-
mal celecoxib-treated HCT 15 cells have demonstrated
shrunken morphology, small ruffles, irregular cytoplasm
Fig. 3 a Phase contrast microscopic and b scanning electron
microscopic images of HCT 15 cells treated with control, free
celecoxib (IC50), liposomal celecoxib (IC50), and empty liposomes
(equivalent to volume of liposomal celecoxib) for 48 h. a In phase
contrast microscopic images, the apoptotic cells are marked with
arrows. All images were taken under the identical instrumental
conditions and presented at the same intensity scale. b In SEM
images, healthy filopodia and lamellipodia are marked with arrow-
heads and truncated lamellipodia and filopodia are marked with
arrows
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detached from substratum, and loss of cell membrane
extensions. However, empty liposome-treated HCT 15
cells showed insignificant changes in cell morphology. It
was observed that the cytotoxicity of liposomal celecoxib
on HCT 15 cells was equivalent to free celecoxib. All the
above results suggest the liposomes nanocarriers could be
a promising choice for celecoxib delivery without loss of
its therapeutic efficacy.
3.7 Cell cycle analysis
Apoptosis fraction was considered as DNA loss resulting in
sub-G1 peak which can be analyzed by flow cytometry. The
amount of PI intercalating to DNA was used as parameter to
determine the cell cycle distribution phases. To find mecha-
nism of apoptosis mediated by free celecoxib and liposomal
celecoxib, cell cycle analysis was performed to check the
changes in sub-G1 peak. HCT 15 cells were treated with free
celecoxib, empty, and celecoxib-loaded liposomes for 48 h and
subjected to flow cytometric analysis. The empty liposome-
treated HCT 15 cells did not show significant apoptosis (1.53±
0.47%) which is insignificant compared with control treatment
(0.92±0.34%; Fig. 4a). In case of free celecoxib and
liposomal celecoxib, treatment resulted in 34.14±0.47% and
24.21±0.75% of apoptosis, respectively (Fig. 4a). Results
indicate that the apoptosis induced by liposomal celecoxib
was slightly lower than free celecoxib treatment. This might
be due to lower intracellular level of liposomal celecoxib and
slow release of celecoxib from liposomes. Increased apopto-
sis of free celecoxib treatment results from increased
availability or intracellular concentrations of celecoxib in
HCT 15 cells (Celia et al. 2008).
3.8 Epi-fluorescence microscopic analysis
The majority of anticancer agents including celecoxib
interact with nuclear DNA to cause DNA damage thus
preventing cell proliferation and inducing apoptosis (Wei et
al. 2008; Danhier et al. 2009; Jung et al. 2009; Munoz-
Bonilla et al. 2009; Yuan et al. 2010). The control and
treated HCT 15 cells were stained with DAPI. The control
HCT 15 cells displayed normal, round nuclear morphology,
and homogenous fluorescence without any DNA fragmen-
tation. In a similar way, the empty liposome-treated HCT 15
cells have also displayed no sign of DNA damage (Fig. 4b).
This further substantiates biocompatibility of the liposo-
mal carrier. Conversely, free celecoxib- and liposomal
celecoxib-treated HCT 15 cells have displayed typical
morphological characteristics of apoptosis which include
shrunken nuclear size, chromatin condensation, and much
brighter nuclear fragmentation compared with control.
The ability of liposomal celecoxib to induce apoptosis
suggests that the liposomalization did not affect apoptosis
induction by celecoxib.
Fig. 4 a Cell cycle analysis of HCT 15 cells treated with control
(PBS), celecoxib (IC50), empty liposomes (equivalent to volume of
liposomal celecoxib), and liposomal celecoxib (IC50) for 48 h. M1-
Sub-G1 Phase, M2-G0/G1 Phase, M3-S Phase, and M4-G2/M Phase.
b DAPI nuclear staining of HCT 15 cells treated with control, free
celecoxib (IC50), empty liposomes (equivalent to volume of liposomal
celecoxib), and liposomal celecoxib (IC50) for 48 h (epi-fluorescence
microscopic image at ×20 and scale bars, 10 μm). DNA fragmentation
and apoptosis are marked with arrows
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3.9 Inhibition of DMBA-induced tumor in rat model
In this study, tumors in reversible stage (90 days after
injection of DMBA) were used (Samy et al. 2006). The
maximum tolerated dose of celecoxib in rodents has been
reported as 1 mg/kg of body weight (Paulson et al.
2000). Figure 5a–c shows changes in body weight, tumor
volume, and dissected tumors before and after treatment,
respectively. Compared with negative control (group I),
the untreated tumor-bearing control (group II) displayed
decrease in body weight. Group III treated with free
celecoxib resulted in significant decrease in tumor volume
compared with control cancer (group II; Fig. 5b). But the
reduction was less than liposomal celecoxib treatment
which can be attributed reduced availability of celecoxib
at tumor site and less half life of celecoxib in blood.
Decrease in body weight after celecoxib treatment might
be due to toxicity associated with celecoxib and weakness
Table 2 The effect of liposomal celecoxib on antioxidant enzymes of
liver in DMBA-induced cancer in rats
Groups Treatment groups Superoxide
dismutase
Lipid
peroxidation
Group I Normal control 3.45±0.07* 0.79±0.06*
Group II Cancer control 1.27±0.17 1.95±0.27
Group III Cancer + celecoxib 2.31±0.29* 0.71±0.06*
Group IV Cancer + empty liposome 1.39±0.37 1.77±0.47*
Group V Cancer + liposomal celecoxib 3.35±0.21* 1.09±0.08*
Each value represents mean±SD of given number of animals (n=4);
comparison groups I, III, IV, and V with group II
*P<0.01, significant values
Table 3 The effect of liposomal celecoxib on antioxidant enzymes of
kidney in DMBA-induced cancer in rats
Groups Treatment Superoxide
dismutase
Lipid
peroxidation
Group I Normal control 1.55±0.20* 1.70±0.33*
Group II Cancer control 0.69±0.08 2.68±0.24
Group III Cancer + celecoxib 1.36±0.12* 1.91±0.40*
Group IV Cancer + empty liposome 1.09±0.20* 2.15±0.24*
Group V Cancer + liposomal celecoxib 1.18±0.08* 1.69±0.18*
Each value represents mean±SD of given number of animals (n=4);
comparison groups I, III, IV, and V with group II
*P<0.01, significant values
Fig. 5 Effect of PBS (control),
free celecoxib, empty lipo-
somes, and liposomal celecoxib
on DMBA-induced rat tumor
model. Body weight loss of
treated groups compared with
control (n=6) (a). Decrease in
tumor volume (cubic milli-
meters) after 30 days of treat-
ment (tumor induction 90 days+
treatment 30 days=120 days)
(b). The images of dissected
tumor before and after 30 days
post-treatment (c). The images
of the tumors in rat model were
shown (d). The results were
presented as mean±SD (n=3).
***P<0.001; **P<0.05, when
compared with control group.
All images were taken under the
identical instrumental conditions
and presented at the same
intensity scale
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in rat after tumor progression. Treatment using empty
liposomes (group IV) produced no significant change in
tumor volume. In case of rats (group V) treated with
liposomal celecoxib, there was significant decrease in
tumor volume with minimal or no change in total body weight
compared to control and other treated groups. It is suggested
that higher concentration of celecoxib at the tumor site might
be attained through EPR effect upon liposomal celecoxib
treatment. This resulted in prominent reduction in tumor
volume and toxicity (insignificant change in bodyweight).We
have also observed that the tumors in control and empty
liposome-treated groups became ulcerated at the end of
120 days, possibly due to aggressive growth (Fig. 5d). The
liposomal celecoxib-treated rat (group V) displayed no
ulceration and tumor-induced mortality when compared with
the control (group II).
3.10 Antioxidant activity
Reactive oxygen species (ROS) are involved in a variety
of important pathological conditions including tumero-
genesis. Free radicals play vital role in tumor promotion
by alteration of cellular metabolic processes and their
scavengers (SOD and LPx). These scavengers inhibit
tumorogenesis which involve in the biotransformation
and detoxification of carcinogens at cytosol and mito-
chondria. Previous studies have shown that anticancer
agents mediate apoptosis in colon cancer cell through
suppression of ROS (Ling et al. 2003). Free radical
scavengers SOD acts as a carcinogen inhibitor during
initiation and promotion/transformation stages of carcino-
genesis (Samy et al. 2006). The effect of liposomal
celecoxib in activation of antioxidant enzymes was
analyzed in liver and kidney tissues. In vitro analysis of
influences of liposomal celecoxib on free radical scaven-
ger enzymes were estimated in the liver supernatants
(Table 2). Results showed significantly elevated levels of
SOD in liposomal celecoxib-treated group compared with
cancer control group. Decreased level of antioxidants in
cancer-bearing animals indicates of oxidative stress, which
may be the cause of lipid peroxidation-induced DNA
damage. The LPx level of cancer control was increased
from normal control. However, the potential reduction of
LPx was observed in the liposomal celecoxib-treated
groups which was comparable to normal control.
SOD and LPx were also recorded in kidney supernatants
(Table 3). The activity of SOD has been increased in the
kidneys of cancer-bearing rats treated with liposomal
celecoxib compared with the untreated rat group. LPx level
was very much influenced by the carcinogen (DMBA) in
the cancer control group. However, the significant reduction
of LPx was observed in the liposomal celecoxib-treated
group, and it was comparable to the normal control group.
The liposomal celecoxib treatment inhibits the tumor cell
growth by antioxidant enzymes which directly resist the
oxidant attack and may protect cells against lipid perox-
idation and DNA damage.
4 Conclusions
This study presents the preparation of liposomal celecoxib
formulation and its effect on colon cancer in vitro and DMBA-
induced cancer in vivo models. The fundamental outcome of
the study is the successful formation of liposomal celecoxib
with appropriate size, high entrapment efficiency, and
hemocompatibility. Liposomal celecoxib- and free
celecoxib-mediated cytotoxicity and apoptosis on HCT 15
cells are comparable. In addition, in vivo study exhibited more
potent tumor growth inhibition by liposomal celecoxib than
free celecoxib in rat tumor model without producing mortality
and side effects. These results suggest that the liposome
carriers may serve as an effective and safe vehicle for
celecoxib delivery in colon cancer chemotherapy. This
preliminary approach of liposome-mediated targeted delivery
might overcome side effects caused by celecoxib. In this
regard, detailed preclinical studies are required before
advancing into human application.
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